Effectiveness of maternal pertussis vaccination in protecting newborn: A matched case-control study

Introduction: The objective was to estimate the effectiveness of maternal pertussis vaccination in protecting infants aged < 2 months. Methods: We performed a case-control study. Laboratory-confirmed cases aged < 8 weeks at disease onset were identified and 2-4 matched-controls born within +/- 15 days of the case were included. Information was obtained from healthcare providers and maternal interviews. Odds ratios (OR) were calculated using multivariable conditional logistic regression. Vaccine effectiveness (VE) was estimated as (1 - OR) x 100%. Results: 47 cases and 124 controls were studied. The mean age (in days) (39.8 +/- 12.7 vs. 40.8 +/- 13.2), weeks of gestation (38.8 vs. 39.1, p = 0.43) and mean birth weight (3.309 vs. 3.253 kg, p = 0.55) were comparable between cases and controls. Mothers of cases were less frequently vaccinated in the third trimester (59.6% vs. 83.9%, p < 0.001). The VE of maternal vaccination in pregnancy was 88.0% (95%CI 53.8%-96.5%), and was slightly higher in those vaccinated before the 32nd week of gestation (88.5% vs 87.8%). Conclusion: Pertussis vaccination in pregnancy is very effective in reducing pertussis in children aged < 2 months. Vaccination before and after the 32nd week of pregnancy are equally effective in reducing the risk of pertussis. (c) 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.